Investigational drug · Phase 2
AK130
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Biliary Tract Cancer, Hepatocellular Carcinoma, Pancreatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "AK130"
First trial start
2024
Sep 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK130", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AK130" as an intervention, largest first.
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)Pivotal-lookingRecruiting
AkesoIndustry
NCT06530251 · 280 participants (planned) · Start Sep 24, 2024 · Primary completion Jun 2026
Drug: AK112; Cadonilimab and 4 more · For: Hepatocellular Carcinoma
Sites: Beijing, China; Jinan, China
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic CancerPivotal-lookingRecruiting
AkesoIndustry
NCT07114315 · 160 participants (planned) · Start Sep 19, 2025 · Primary completion Aug 2027
Drug: AK112; AK130 · For: Pancreatic Cancer
Sites: Shanghai, China; Tianjin, China
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerPivotal-lookingRecruiting
AkesoIndustry
NCT06938321 · 135 participants (planned) · Start Apr 30, 2025 · Primary completion May 2027
Drug: AK112; AK130 · For: Biliary Tract Cancer
Sites: Beijing, China
AkesoIndustry
NCT05653284 · 19 participants · Start Feb 9, 2023 · Primary completion Dec 12, 2023
Drug: AK130 · For: Advanced Malignant Tumors
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Biliary Tract Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.